Good to see a bit of balance in the commentary from Pittwater.
I am unsure of dakfifity's or SS9's motivation but it seems to me that they are fanboys of the previous management team or part of it. Donnison reigned over the MLA business along with Lewis and delivered loss after loss - some to the tune of 7 figures, year after year. After the clean-out we got a modest return last year, and the segment reports at the half showed a stellar performance for the "old" MLA business. Why couldn't the previous team deliver that result rather than giving away a third of the company to gain Medivet?
As to SS9's coments; the previous owners got their money and ran, maybe they know how difficult it has been and will be? As for the "equine performance" business my understanding is that the more distance the company can put between this and the continuing business the better. Even the US business didn't get heavily involved in these products. As for Delk, the latest I heard was that he was still running the US operations and was basically the head of all Medivet.
As the company has reported, they are investing in R&D to support this business. This sort of effort takes deep pockets. VetStem last year reported doing a deal with Aritana to the tune of $US4.5m to develop stem-cell products. MLA doesn't have that sort of money and as Pittwater points out, there appears to be an enormous amount of money washing around the US at the moment. Maybe this is a good time to tap into it.
IMO the current team has achieved more in the past 12 months than the previous management team ever did or would. Dakfifty's comments about the share price are a bit of a joke. As I have previously stated, a spike in the share price built on speculation can't be sustained. Positive results from the old MLA business repeated over time will deliver real results and be reflected in the share price sooner rather than later.
DYOR, IMHO etc.
MLA Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
